Arvinas (ARVN) Q3 2025: $100M Buyback, Cost Reset Extends Cash Runway to 2028

November 5, 2025 | By EarningsIQ Research

Arvinas executed a decisive capital return and cost control pivot, authorizing a $100 million buyback and reducing R&D and G&A spend, extending its cash runway into the second half of 2028. The company’s pipeline momentum in oncology and neuroscience is accelerating, with early-stage clinical and preclinical data readouts in the next year. Investors are watching for clinical validation of Arvinas’ differentiated PROTAC platform and the outcome of the strategic out-licensing of VetDagastrat ahead of a pivotal FDA decision in 2026.

Summary

• Capital Return Pivot: $100 million buyback and operating cost reset reinforce balance sheet flexibility.
• Pipeline Acceleration: Multiple first-in-class PROTAC assets advance in oncology and neuroscience, with key data readouts approaching.
• Partnering and Portfolio Focus: Out-licensing VetDagastrat sharpens focus on wholly owned pipeline and early-stage asset differentiation.

Performance Analysis

Arvinas’ third quarter underscored a strategic shift from heavy late-stage spend to a capital-efficient, early-stage pipeline model. Revenue declined sharply year-over-year due to the wind-down of Novartis collaboration revenue, partially offset by a $20 million milestone payment. The company’s cash position remains robust, with $787.6 million on hand, reflecting both disciplined expense management and the absence of new large upfront payments.

Operating expenses dropped materially as the company exited its 101 College Street lease and reduced headcount, driving G&A down by over 70% and R&D by more than 25% year-over-year. The planned reduction in VetDagastrat (VetDag) spend, as the asset transitions toward out-licensing, will further lower costs. Non-GAAP quarterly expenses were $71.5 million, with a stated target to keep the run rate below $75 million and full-year 2026 non-GAAP expenses under $300 million.

• Cost Reset Impact: Lease termination and lower personnel costs drove G&A to $21 million, down from $75.8 million a year ago.
• R&D Mix Shift: Spend decreased as VetDag and LuxDeg programs wound down, with incremental investment in the KRAS program reflecting pipeline reprioritization.
• Buyback Execution: 2.56 million shares repurchased at an average $7.91, signaling management’s view of undervaluation.

Management’s focus on capital efficiency and portfolio prioritization sets a new baseline for operating leverage as clinical catalysts approach in 2026.

Executive Commentary

Strategic Positioning

1. Portfolio Refocus and Capital Allocation Discipline

Arvinas’ decision to out-license VetDagastrat (ER-positive, HER2-negative advanced breast cancer asset) and reduce late-stage spend marks a deliberate pivot toward early-stage innovation and capital returns. The $100 million buyback authorization and aggressive cost reductions reinforce a commitment to shareholder value and balance sheet strength, providing flexibility to navigate clinical inflection points.

2. Pipeline Depth and First-Mover Differentiation

The company’s pipeline is entering a “data-rich” period with multiple clinical and preclinical readouts across oncology (BCL6, KRAS G12D) and neuroscience (LRRK2, Poly2AR). Notably, ARV102, a brain-penetrant LRRK2 degrader, and ARV806, a highly potent KRAS G12D degrader, are positioned to address significant unmet needs and demonstrate platform differentiation versus existing inhibitors. Early clinical data show robust biomarker engagement and tolerability, supporting the thesis of deeper and more durable responses.

3. Platform Versatility and Therapeutic Breadth

Arvinas is leveraging its PROTAC platform (proteolysis-targeting chimera, a modality that induces targeted protein degradation) to expand into neuromuscular and immuno-oncology indications. Programs targeting polyglutamine-expanded androgen receptor (SBMA) and HPK1 (immuno-oncology) highlight the breadth and adaptability of the technology, with first-in-human studies targeted for 2026.

4. Strategic Partnering Optionality

Management signaled openness to business development (BD) opportunities across the pipeline, particularly for assets with broad commercial potential. With all pipeline assets currently fully owned (except VetDagastrat, co-developed with Pfizer), Arvinas retains strategic flexibility to license, partner, or advance programs internally as clinical data emerges.

5. Financial Runway and Clinical Execution

With cash runway into the second half of 2028, Arvinas is positioned to fund multiple Phase 1 and 2 studies across its core pipeline. The shift from costly late-stage trials to a diversified early-stage portfolio reduces financial risk and enhances optionality, while maintaining exposure to high-impact clinical catalysts.

Key Considerations

Arvinas’ Q3 marks a turning point in capital allocation strategy and operational discipline, with implications for pipeline advancement, risk profile, and valuation. The quarter’s developments raise several key considerations for investors:

Key Considerations:

• Buyback and Expense Control: The $100 million buyback and G&A/R&D reductions signal management’s confidence in intrinsic value and a commitment to disciplined capital allocation.
• Pipeline Readout Cadence: Multiple early-stage clinical and preclinical data readouts are expected in 2026, including pivotal biomarker and efficacy updates for ARV102 and ARV806.
• VetDagastrat Out-Licensing: The outcome of the VetDagastrat partnership process and FDA review (PDUFA June 2026) will determine near-term non-dilutive capital and commercial focus.
• Platform Validation Risk: The ability of Arvinas’ PROTAC platform to translate biomarker engagement into clinical efficacy remains the critical gating factor for long-term value creation.
• Partnering and Portfolio Choices: Management’s willingness to partner or retain programs will shape both capital requirements and upside capture as data matures.

Risks

Arvinas faces execution risk in translating early biomarker and preclinical data into meaningful clinical efficacy, especially in heterogeneous diseases like Parkinson’s and oncology. The success of strategic out-licensing, particularly for VetDagastrat, is uncertain and may impact near-term revenue and focus. Platform risk remains if PROTAC assets do not demonstrate clear clinical differentiation over existing therapies. Competition in targeted protein degradation and immuno-oncology is intensifying, increasing pressure for first-mover advantage and compelling clinical data.

Forward Outlook

For Q4 and into 2026, Arvinas guided to:

• Quarterly non-GAAP operating expense run rate below $75 million
• Full-year 2026 non-GAAP expenses below $300 million

For full-year 2025 and beyond, management maintained its cash runway guidance into 2H 2028, with incremental cost savings from VetDagastrat ramp-down. Key catalysts include:

• Phase 1 and preclinical data readouts for ARV102, ARV806, and ARV393 in 2026
• Partner selection and potential launch readiness for VetDagastrat ahead of June 2026 PDUFA date

Takeaways

Arvinas’ Q3 signals a strategic reset, prioritizing capital efficiency, pipeline breadth, and shareholder returns.

• Expense Reset Drives Flexibility: Cost reductions and buybacks allow Arvinas to weather longer development cycles and clinical risk while retaining upside from multiple pipeline shots on goal.
• Clinical Validation is Critical: The next 12-18 months will test the clinical promise of Arvinas’ differentiated PROTAC assets, with biomarker and efficacy data needed to support platform value.
• Partnerships and Portfolio Choices Loom: Execution on VetDagastrat out-licensing and strategic partnering will determine near-term capital inflows and resource allocation for high-priority programs.

Conclusion

Arvinas enters 2026 with a streamlined cost base, a fortified balance sheet, and a pipeline poised for clinical inflection. The company’s success now hinges on translating early scientific leadership into clinical and commercial milestones, with multiple catalysts ahead to confirm platform differentiation and unlock shareholder value.

Industry Read-Through

Arvinas’ cost reset and portfolio focus reflect a broader biopharma trend of shifting from late-stage capital intensity to early-stage innovation with disciplined capital allocation. The company’s aggressive expense management and buyback signal a new era of financial prudence among clinical-stage biotechs. The pipeline’s focus on first-in-class protein degraders in both oncology and neuroscience underscores the growing industry emphasis on modality innovation and platform breadth. Other biotechs in the targeted degradation and neuro-oncology spaces will be closely watched for similar capital discipline and partnering dynamics, especially as competition for clinical validation and commercial partnerships intensifies.

ARVN Healthcare Biotechnology Pipeline Protein Degradation Buyback Oncology Neuroscience